Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMTRYG vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of chronic hepatitis C virus (HCV) genotype 4 infection without cirrhosis or with compensated cirrhosis,Treatment of chronic HCV genotype 1 infection (with ribavirin or as part of combination therapy)
Mild to moderate pain,Pain accompanied by fever
2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is 12-14 hours in healthy adults, allowing once-daily dosing. In renal impairment (Cr Cl <30 m L/min), half-life prolongs to 24-36 hours requiring dose adjustment.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Ombitasvir: primarily metabolized by CYP3A4; Paritaprevir: primarily metabolized by CYP3A4; Ritonavir: primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal excretion unchanged (approximately 70%), with 30% metabolized hepatically and excreted in feces via bile. Renal clearance accounts for ~60% of total clearance.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Approximately 95% bound to serum albumin.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and plasma with limited tissue penetration.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: 60-80% (first-pass effect); Subcutaneous: 90-100%.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No dose adjustment required for GFR ≥30 m L/min; avoid use if GFR <30 m L/min.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No dose adjustment required for Child-Pugh A or B; not recommended in Child-Pugh C due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Not approved for pediatric patients <18 years; safety and efficacy not established.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No dose adjustment required based on age; monitor for taste disturbance and renal function.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
WARNING: HEPATITIS B VIRUS REACTIVATION — Test all patients for evidence of current or prior HBV infection before initiating treatment. HBV reactivation has been reported in patients coinfected with HCV and HBV, which can result in fulminant hepatitis, hepatic failure, and death.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Risk of hepatitis B virus reactivation,Hepatic decompensation/hepatic failure in patients with cirrhosis,ALT elevations and hepatic injury,Risk of drug interactions (significant CYP3A4 inhibition),Use with ribavirin: ribavirin-related adverse effects (e.g., anemia, teratogenicity)
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Severe hepatic impairment (Child-Pugh C),Known hypersensitivity to ombitasvir, paritaprevir, ritonavir, or any component of the formulation,Coadministration with drugs highly dependent on CYP3A4 for clearance (e.g., alfuzosin, amiodarone, sildenafil when used for pulmonary arterial hypertension, ergot derivatives, lovastatin, simvastatin, midazolam, triazolam),Moderate to severe hepatic impairment in patients with cirrhosis (Child-Pugh B and C)
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No clinically significant food interactions reported.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Pregnancy Category X: contraindicated in pregnancy. First trimester: major congenital malformations (e.g., neural tube defects, cardiac anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, neonatal renal failure. Risk is dose-dependent.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Contraindicated during breastfeeding. M/P ratio not established; drug excreted into breast milk. Potential for serious adverse effects in nursing infant (renal toxicity).
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended due to contraindication.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
OMTRYG (triptorelin pamoate) is a Gn RH agonist used for advanced prostate cancer. Monitor for tumor flare at therapy initiation; consider antiandrogen coadministration for first month. Baseline and periodic serum testosterone and PSA levels are essential. Caution in patients with spinal cord compression or urinary tract obstruction. Risk of QT prolongation; assess electrolytes and ECG in at-risk patients. Depot formulation provides 6-month coverage.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
OMTRYG is injected every 6 months by a healthcare provider.,You may experience a temporary increase in bone pain or urinary symptoms during the first few weeks.,Report new or worsening pain, difficulty urinating, or leg weakness immediately.,Hot flashes, decreased libido, and erectile dysfunction are common.,Do not stop treatment without consulting your doctor.,Keep all scheduled injections; missed doses can reduce effectiveness.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMTRYG vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
OMTRYG is a HMG-CoA Reductase Inhibitor (Statin) that works by OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMTRYG and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMTRYG is: 2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OMTRYG and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OMTRYG is classified as Category C. Pregnancy Category X: contraindicated in pregnancy. First trimester: major congenital malformations (e.g., neural tube defects, cardiac anomalies). Second and third trimesters: fet. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.